의료 2차 소견 시장

Medical Second Opinion Market

상품코드HCIT2076
발행기관DataM Intelligence
발행일2023.02.01
페이지 수200 Pages
포맷PDF + EXCEL
커버리지Global

6,525,00011,775,000

보고서 요약(국문)

시장 개요
전 세계 의료 2차 소견 시장 규모는 2022년 YY백만 달러였으며, 2030년까지 YY백만 달러에 이를 것으로 예상됩니다. 예측 기간(2023~2030년) 동안 연평균 성장률(CAGR)은 14%입니다.
의료 2차 소견은 다른 의사가 제안한 치료법을 확정하거나 수정하는 데 도움을 주는 의사결정 지원 도구입니다. 의료 2차 소견은 진단, 치료 및 예후에 중대한 영향을 미칠 수 있습니다. 환자는 최적의 치료를 받고 불필요한 위험을 피할 수 있으며, 의사는 법적 소송 위험을 줄일 수 있습니다. 의료기관은 치료 효과 증대, 품질 보증, 불필요한 수술 및 치료 비용 절감 등의 이점을 누릴 수 있습니다. 그러나 이 도구를 부적절하게 사용할 경우 불필요한 의료 비용이 발생할 수 있습니다.
시장 동향
의료 2차 소견 시장 성장은 진단 개선에 대한 수요 증가, 비용 절감, 정부 정책 지원 등 여러 요인에 의해 주도됩니다.
특히 진단 개선에 대한 수요 증가가 전 세계 의료 2차 소견 시장 성장을 견인하고 있습니다.

대부분의 사람들은 일생 동안 적어도 한 번은 진단 오류를 경험하며, 때로는 이러한 오류가 심각한 결과를 초래하기도 합니다. 미국 국립 의학 아카데미의 보고서에 따르면, 매년 외래 진료를 받는 미국 성인의 약 5%가 진단 오류를 경험하는 것으로 추정됩니다. 수십 년에 걸친 부검 연구에 따르면 진단 오류는 환자 사망의 약 10%에 기여하는 것으로 나타났습니다. 의료 기록 검토 결과, 진단 오류는 병원 내 유해 사례의 6%에서 17%를 차지하는 것으로 나타났습니다. 더욱이, 진단 오류는 의료 과실 소송에서 가장 흔한 유형이며, 다른 소송에 비해 환자 사망으로 이어질 가능성이 거의 두 배나 높습니다.
메이요 클리닉에 따르면, 두 번째 의견을 구한 환자의 20% 이상이 1차 진료 의사로부터 오진을 받았습니다. 처음 진단이 정확했던 환자는 12%에 불과했으며, 나머지는 어떤 면에서든 진단이 달랐습니다. 환자의 21%에서 두 번째 의견은 첫 번째 진단과 "확연히 다른" 진단을 제시했습니다. 67%의 경우 진단은 부분적으로만 맞았지만, 두 번째 의견을 통해 "더욱 명확하고 정교해진" 것으로 나타났습니다. 환자들이 선택하는 치료법은 수술 또는 그 대안의 가치에 대한 지역 의료진의 의견에 크게 좌우됩니다. 만성 요통에 대해 특정 수술과 같은 치료법을 처방할 경우, 환자의 건강 상태가 악화될 수 있습니다. 장기적인 긍정적 효과를 입증하는 근거가 부족하고, 물리치료와 같이 비용이 저렴한 치료법이 존재하기 때문입니다. 두 번째 의견을 통해 불필요한 수술을 피할 수 있으며, 이로 인해 수천 건의 불필요한 사망 사례가 발생했다는 주장도 있습니다. 이러한 불필요한 치료는 정부에 수십억 달러의 비용 부담을 안겨주었지만, 두 번째 의견을 통해 이를 예방할 수 있습니다.
의료 두 번째 의견의 중요성에 대한 인식 부족은 전 세계 의료 두 번째 의견 시장 성장을 저해할 것입니다.
특히 개발도상국에서 두 번째 의견을 구하는 것에 대한 인식 부족과 주저함이 시장 성장을 저해하는 주요 요인입니다.

산업 분석.

글로벌 의료 2차 소견 시장 보고서는 포터의 5가지 경쟁력 분석, 혁신, 신제품 출시, 가격 분석 등 다양한 산업 요인을 기반으로 시장에 대한 심층 분석을 제공합니다.
COVID-19 영향 분석
글로벌 의료 2차 소견 시장은 COVID-19의 긍정적인 영향을 받았으며, 팬데믹이 지속됨에 따라 성장을 견인했습니다. 북미 의료 2차 소견 시장은 팬데믹 기간 동안 글로벌 시장에서 가장 높은 점유율을 차지했으며, 예측 기간 동안 상당한 성장률을 기록할 것으로 예상됩니다. 북미 지역 시장 성장의 주요 동인은 인구 증가와 건강 보험 회사 및 병원과 같은 주요 서비스 제공업체입니다.
세그먼트 분석
신경계 질환은 예측 기간(2023-2030년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
이 중 신경계 질환은 예측 기간(2023-2030년) 동안 시장에서 지배적인 점유율을 차지할 것으로 예상됩니다. 주의력 결핍 과잉 행동 장애, 파킨슨병, 우울증, 양극성 장애 등 많은 신경계 질환은 진단이 어렵고 오진으로 이어지는 경우가 많습니다. 파킨슨병 재단에 따르면 파킨슨병 환자의 약 25~30%가 오진을 받는데, 이는 매우 높은 수치입니다. 마찬가지로 양극성 장애 환자의 약 69%가 초기 진단에서 오진을 받습니다. 숙련된 내과 전문의나 일반 신경과 전문의조차도 파킨슨병 진단에 어려움을 겪을 수 있으며, 특히 파킨슨병 경험이 부족한 경우 더욱 그렇습니다. 파킨슨병 재단은 파킨슨병 진단을 받은 사람들에게 운동 장애 전문의이자 파킨슨병에 대한 풍부한 경험을 가진 신경과 전문의에게 두 번째 의견을 구하는 것을 권장합니다. 마찬가지로 우울증의 경우에도 정신과 전문의에게 두 번째 의견을 구하는 것이 항상 권장됩니다.
지역 분석
북미 지역은 전 세계 의료 2차 소견 시장을 주도하고 있습니다.
북미는 2021년 의료 2차 소견 시장을 선도했으며, 높은 인식 수준, 선진적인 의료 인프라, 그리고 우호적인 정부 정책에 힘입어 예측 기간(2023~2030년) 동안에도 가장 큰 시장 규모를 유지할 것으로 예상됩니다. 이 지역에는 WorldCare International Inc.와 같이 환자의 2차 소견을 지원하는 여러 기관이 활동하고 있습니다. WorldCare International Inc.는 회원들을 진단 확인, 치료 계획 검토, 질문 답변, 시의적절한 독립적인 2차 소견 제공을 위해 협력하는 전문가 팀과 연결해 줍니다. 정부 또한 이 지역에 유리한 정책과 프로그램을 시행하고 있으며, 미국과 같은 국가에서는 의료 보험을 통해 비용을 상환해 줍니다. 메디케어는 응급 상황이 아닌 수술의 경우 2차 소견 비용을 일부 지원합니다. 또한 1차 소견과 2차 소견이 다를 경우 3차 소견 비용도 지원합니다.
이 지역의 주요 서비스 제공업체는 건강 보험 회사와 병원이며, 시장 성장을 이끄는 주요 요인은 북미 지역의 노인 인구 증가입니다. 예를 들어, 알츠하이머 협회는 2022년에 65세 이상 미국인 650만 명이 알츠하이머병을 앓을 것으로 추산했으며, 2050년에는 1,270만 명에 이를 것으로 예상했습니다. 또한, 알츠하이머병은 2020년과 2021년 미국에서 7번째로 흔한 사망 원인이었습니다. 미국 인구의 고령화가 진행됨에 따라 신경퇴행성 질환을 안고 살아가는 사람들의 수는 계속 증가하고 있습니다. 파킨슨병 재단에 따르면 매년 6만 명의 미국인이 파킨슨병 진단을 받고 있습니다. 또한, 2022년 말까지 알츠하이머병 및 기타 치매로 인한 국가적 비용은 3,210억 달러에 달할 것이며, 2050년에는 거의 1조 달러에 이를 수 있습니다. 더 나아가, 의료 서비스의 발전과 빠른 디지털화로 인한 온라인 상담의 중요성 증가는 수익 증대에 크게 기여했습니다.

경쟁 환경
기업, 의료 보험사, 병원들은 전 세계 시장에서 경쟁력 있는 2차 소견 서비스를 제공하며 빠르게 성장하고 있습니다. 의료 보험에 가입하고 더 나은 치료를 위해 재평가를 원하는 환자들이 늘어남에 따라 이러한 의료 서비스 제공업체들은 호황을 누리고 있습니다. 시장의 주요 업체로는 WorldCare Inc., Cynergy Care, Mediguide International LLC, AXA PPP Healthcare, Cleveland Clinic, Helsana Group, Teladoc Health, GrandOpinion, Lybrate, Partners Healthcare, Grand Rounds Inc. 등이 있습니다. 모든 의료 서비스 제공업체는 환자의 수요를 신속하고 효율적으로 충족하기 위해 노력하며, 이는 글로벌 시장 성장에 기여하고 있습니다. 예를 들어, 2020년 1월 10일 Alliance Healthcare는 Inova Care와 제휴하여 지역 시장 기회를 모색했습니다. 또한, 2022년 1월 19일 AXA Health는 Peppy와 협력하여 AXA Health의 대기업 고객사 직원들에게 맞춤형 전문가 지원을 제공하기 시작했습니다.
Mediguide International LLC
개요:
MediGuide는 1999년 델라웨어에서 설립되었으며, 현재는 MediGuide International, LLC로 사명을 변경했습니다. MediGuide International, LLC는 7개국에 사무소를 두고 5개 대륙에 걸쳐 사업을 확장했으며, 50개국 이상의 고객을 보유하고 있습니다. MediGuide International, LLC는 152개국 이상에서 회원들의 의료 2차 소견 사례를 관리하고 있으며, 수백만 명의 활성 회원을 보유하고 있습니다.
제품 포트폴리오:
MediGuide International LLC의 의료 2차 소견 서비스 포트폴리오에는 MediGuide MSO가 포함됩니다.
글로벌 의료 2차 소견 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량으로 구성되어 있습니다.

보고서 요약(영어 원문)

Market Overview
The global medical second opinion market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 14% during the forecast period (2023-2030).
A medical second opinion is a decision-support tool for ratifying or modifying a suggested treatment by another physician. A medical second opinion may critically influence the diagnosis, treatment, and prognosis. The patient can benefit from treatment optimization and avoid unnecessary risks. Physicians can benefit from less exposure to legal claims, and healthcare organizations can benefit from increased treatment, quality assurance, and cost-saving from unnecessary surgery and treatments. Nevertheless, the injudicious use of this tool can provoke unnecessary medical costs.
Market Dynamics
The medical second opinion market growth is driven by several factors, such as the increased need for improved diagnosis, reduced financial cost, and favorable government initiatives.
The increasing need for improved diagnosis drives the growth of the global medical second opinion market.
Most people experience at least one diagnostic error in their lifetime, and sometimes these errors lead to devastating consequences. According to a report by the National Academy of Medicine, it is estimated that 5% of U.S. adults who seek outpatient care each year experience a diagnostic error. Postmortem examination research over decades shows that diagnostic errors contribute to approximately 10% of patient deaths. Medical record reviews suggest that diagnostic errors account for 6% to 17% of hospital adverse events. Moreover, diagnostic errors are the leading type of paid medical malpractice claims and are almost twice as likely to have resulted in the patient’s death compared to other claims.
According to Mayo Clinic, more than 20% of patients who sought a second opinion had initially been misdiagnosed by their primary care providers. Only 12% had their cases correctly diagnosed initially; the rest of the diagnoses differed in some aspect. In 21% of patient cases, the second opinion indicated a “distinctly different” diagnosis from the first diagnosis. In 67% of cases, the diagnoses were partly correct but “better defined/refined” by a second opinion. Treatment choices that patients usually go for are determined largely by local medical opinions concerning the value of surgery or its alternative. Health outcomes are threatened when doctors prescribe a treatment like a certain surgery for chronic back pain. There is no evidence proving positive long-term outcomes, and a less expensive treatment option, like physical therapy, is available. A medical second opinion can avoid many unnecessary surgeries that are claimed to have led to thousands of avoidable deaths. These unnecessary treatment options led to billions on the government, which can be avoided in my medical second opinion.
The lack of awareness will hamper the global medical second opinion market growth.
However, the lack of awareness and hesitance toward opting for a second medical opinion in developing nations is the major factor hampering the market growth.
Industry analysis.
The global medical second opinion market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, Etc.
COVID-19 Impact Analysis
The global medical second opinion market was positively impacted by COVID-19 and drove growth as the pandemic continues. North American medical second opinion market produced the highest share of the global market during the pandemic and is expected to record a significant growth rate over the forecast period. Major drivers for the market growth in the North American region are the increasing population and major service providers such as health insurance companies and hospitals.
Segment Analysis
Neurological disorders are expected to grow at the fastest CAGR during the forecast period (2023-2030).
Among these, neurological disorders are expected to have a dominant market share over the period forecast (2023-2030). Attention deficit hyperactivity disorder, Parkinson's disorder, depression, bipolar disorders, and many more neurological disorders are tough to diagnose and lead to many misdiagnoses. According to Parkinson's Foundation, around 25-30% of Parkinson's disorder is misdiagnosed, which is a very high number. Similarly, around 69% of bipolar patients receive misdiagnosis initially. Even well-trained internists and general neurologists can have trouble diagnosing Parkinson's disease, especially if they've had little experience with it. Parkinson's Foundation suggests that people diagnosed with Parkinson's consider getting a second opinion from a neurologist specializing in movement disorders and who has extensive experience with Parkinson's. Similarly, in depression, a second opinion from a psychiatrist is always suggested.
Geographical Analysis
The North American region oppresses the global medical second opinion market.
North America commanded the medical second opinion market in 2021 and is estimated to hold the largest market size over the forecast period (2023-2030), owing to a highly aware population, advanced healthcare infrastructure, and favorable government initiatives. Many organizations work in the region to assist patients with the second opinion, such as WorldCare International Inc., which connects members with teams of specialists who work together to confirm diagnoses, review treatment plans, answer questions, and deliver timely independent second opinions. The government also initiates favorable policies and programs in the region and provides reimbursements through medical insurance in countries like U.S. Medicare covers a second opinion in some cases for surgery that isn't an emergency. Medicare also helps pay for a third opinion if the first and second opinions differ.
The important service providers in the region comprise health insurance companies and hospitals, and the object of driving the market's growth is an upsurge in the geriatric population in the North American region. For instance, the Alzheimer's Association estimated that 6.5 million Americans age 65 and older would live with Alzheimer's in 2022; by 2050, 12.7 million will be there. Also, Alzheimer's is the seventh-leading cause of death in the United States in 2020 and 2021. As the U.S. population ages, the number of people living with neurodegenerative diseases continues to grow; per Parkinson's Foundation, 60,000 Americans are diagnosed with P.D. each year. In addition, by the end of 2022, Alzheimer's and other dementias will cost the nation $321 billion, and by 2050, these costs could reach nearly $1 trillion. Furthermore, the enhancement of more healthcare services and the importance of online consultancy owing to fast digitization have also donated considerably to the revenue.
Competitive Landscape
Companies, healthcare insurance providers, and hospitals are emerging rapidly with competitive second opinion services in the global market. These healthcare providers are booming due to the wide variety of patients taking medical insurance and seeking a second evaluation for a better remedy. Some of the major key players in the market are WorldCare Inc., Cynergy Care, Mediguide International LLC, AXA PPP Healthcare, Cleveland Clinic, Helsana Group, Teladoc Health, GrandOpinion, Lybrate, Partners Healthcare, and Grand Rounds Inc. All the healthcare providers are working towards meeting patient demand quickly and efficiently, thus helping the global market. For instance, on January 10, 2020, Alliance Healthcare partnered with Inova Care to explore regional opportunities. Also, on 19 JANUARY 2022, AXA Health teamed up with Peppy to offer personalized, expert support to employees of AXA Health’s large corporate clients.
Mediguide International LLC
Overview:
MediGuide was established in 1999 in Delaware with now renamed as MediGuide International, LLC. MediGuide International, LLC has spread its business across 5 continents through Offices in 7 countries, with clients from more than 50 countries managing their member’s medical second opinion cases in more than 152 countries and has an active membership base of millions of members.
Product Portfolio:
Mediguide International LLC’s services portfolio for medical second opinion has MediGuide MSO.
The global medical second opinion market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

상세 목차

Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Need for Improved Diagnosis
4.1.1.2. Increased Incidences of Neurological Disorders
4.1.2. Restraints
4.1.2.1. Lack of Awareness
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Disorder
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Segment
7.1.2. Market Attractiveness Index, By Disorder Segment
7.2. Cancer
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Diabetes
7.4. Cardiac Disorders
7.5. Neurological Disorders
7.6. Ocular Disorders
7.7. Others
8. By Service Provider
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Segment
8.1.2. Market Attractiveness Index, By Application Segment
8.2. Hospitals
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Medical Second Opinion Providing Companies
8.4. Health Insurance Companies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Provider
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. The U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Provider
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. The U.K.
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Provider
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Provider
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Provider
10. Competitive Landscape
10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking
11. Company Profiles
11.1. Mediguide International LLC
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. WorldCare Inc.
11.3. Cynergy Care
11.4. AXA PPP Healthcare
11.5. Cleveland Clinic
11.6. Helsana Group
11.7. Teladoc Health
11.8. GrandOpinion
11.9. Lybrate, Partners Healthcare
11.10. Grand Rounds Inc.
LIST NOT EXHAUSTIVE
12. DataM
12.1. Appendix
12.2. About Us and Services
12.3. Contact Us

언급된 주요 기업들

Mediguide International LLC, WorldCare Inc., Cynergy Care, AXA PPP Healthcare, Cleveland Clinic, Helsana Group, Teladoc Health, GrandOpinion, Lybrate, Partners Healthcare, Grand Rounds Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Medical Second Opinion Market Value, By Disorder, 2023, 2027 & 2031 ($ Million)

Table 2 Global Medical Second Opinion Market Value, By Service Provider, 2023, 2027 & 2031 ($ Million)

Table 3 Global Medical Second Opinion Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 4 Global Medical Second Opinion Market Value, By Disorder, 2023, 2027 & 2031 ($ Million)

Table 5 Global Medical Second Opinion Market Value, By Disorder, 2022-2031 ($ Million)

Table 6 Global Medical Second Opinion Market Value, By Service Provider, 2023, 2027 & 2031 ($ Million)

Table 7 Global Medical Second Opinion Market Value, By Service Provider, 2022-2031 ($ Million)

Table 8 Global Medical Second Opinion Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 9 Global Medical Second Opinion Market Value, By Region, 2022-2031 ($ Million)

Table 10 North America Medical Second Opinion Market Value, By Disorder, 2022-2031 ($ Million)

Table 11 North America Medical Second Opinion Market Value, By Service Provider, 2022-2031 ($ Million)

Table 12 North America Medical Second Opinion Market Value, By Country, 2022-2031 ($ Million)

Table 13 South America Medical Second Opinion Market Value, By Disorder, 2022-2031 ($ Million)

Table 14 South America Medical Second Opinion Market Value, By Service Provider, 2022-2031 ($ Million)

Table 15 South America Medical Second Opinion Market Value, By Country, 2022-2031 ($ Million)

Table 16 Europe Medical Second Opinion Market Value, By Disorder, 2022-2031 ($ Million)

Table 17 Europe Medical Second Opinion Market Value, By Service Provider, 2022-2031 ($ Million)

Table 18 Europe Medical Second Opinion Market Value, By Country, 2022-2031 ($ Million)

Table 19 Asia-Pacific Medical Second Opinion Market Value, By Disorder, 2022-2031 ($ Million)

Table 20 Asia-Pacific Medical Second Opinion Market Value, By Service Provider, 2022-2031 ($ Million)

Table 21 Asia-Pacific Medical Second Opinion Market Value, By Country, 2022-2031 ($ Million)

Table 22 Middle East & Africa Medical Second Opinion Market Value, By Disorder, 2022-2031 ($ Million)

Table 23 Middle East & Africa Medical Second Opinion Market Value, By Service Provider, 2022-2031 ($ Million)

Table 24 Mediguide International LLC: Overview

Table 25 Mediguide International LLC: Product Portfolio

Table 26 Mediguide International LLC: Key Developments

Table 27 WorldCare Inc.: Overview

Table 28 WorldCare Inc.: Product Portfolio

Table 29 WorldCare Inc.: Key Developments

Table 30 Cynergy Care: Overview

Table 31 Cynergy Care: Product Portfolio

Table 32 Cynergy Care: Key Developments

Table 33 AXA PPP Healthcare: Overview

Table 34 AXA PPP Healthcare: Product Portfolio

Table 35 AXA PPP Healthcare: Key Developments

Table 36 Cleveland Clinic: Overview

Table 37 Cleveland Clinic: Product Portfolio

Table 38 Cleveland Clinic: Key Developments

Table 39 Helsana Group: Overview

Table 40 Helsana Group: Product Portfolio

Table 41 Helsana Group: Key Developments

Table 42 Teladoc Health: Overview

Table 43 Teladoc Health: Product Portfolio

Table 44 Teladoc Health: Key Developments

Table 45 GrandOpinion: Overview

Table 46 GrandOpinion: Product Portfolio

Table 47 GrandOpinion: Key Developments

Table 48 Lybrate: Overview

Table 49 Lybrate: Product Portfolio

Table 50 Lybrate: Key Developments

Table 51 Mass General Brigham: Overview

Table 52 Mass General Brigham: Product Portfolio

Table 53 Mass General Brigham: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Medical Second Opinion Market Share, By Disorder, 2022 & 2031 (%)

Figure 2 Global Medical Second Opinion Market Share, By Service Provider, 2022 & 2031 (%)

Figure 3 Global Medical Second Opinion Market Share, By Region, 2022 & 2031 (%)

Figure 4 Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 5 Global Medical Second Opinion Market Y-o-Y Growth, By Disorder, 2022-2031 (%)

Figure 6 Cancer: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 7 Diabetes: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 8 Cardiac Disorders: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 9 Neurological Disorders: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 10 Ocular Disorders: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 11 Others: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 12 Global Medical Second Opinion Market Y-o-Y Growth, By Service Provider, 2022-2031 (%)

Figure 13 Hospitals: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 14 Medical Second Opinion Providing Companies: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 15 Health Insurance Companies: Global Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 16 Global Medical Second Opinion Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 17 North America Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 18 North America Medical Second Opinion Market Share, By Disorder, 2022 & 2031 (%)

Figure 19 North America Medical Second Opinion Market Share, By Service Provider, 2022 & 2031 (%)

Figure 20 North America Medical Second Opinion Market Share, By Country, 2022 & 2031 (%)

Figure 21 South America Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 22 South America Medical Second Opinion Market Share, By Disorder, 2022 & 2031 (%)

Figure 23 South America Medical Second Opinion Market Share, By Service Provider, 2022 & 2031 (%)

Figure 24 South America Medical Second Opinion Market Share, By Country, 2022 & 2031 (%)

Figure 25 Europe Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 26 Europe Medical Second Opinion Market Share, By Disorder, 2022 & 2031 (%)

Figure 27 Europe Medical Second Opinion Market Share, By Service Provider, 2022 & 2031 (%)

Figure 28 Europe Medical Second Opinion Market Share, By Country, 2022 & 2031 (%)

Figure 29 Asia-Pacific Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 30 Asia-Pacific Medical Second Opinion Market Share, By Disorder, 2022 & 2031 (%)

Figure 31 Asia-Pacific Medical Second Opinion Market Share, By Service Provider, 2022 & 2031 (%)

Figure 32 Asia-Pacific Medical Second Opinion Market Share, By Country, 2022 & 2031 (%)

Figure 33 Middle East & Africa Medical Second Opinion Market Value, 2022-2031 ($ Million)

Figure 34 Middle East & Africa Medical Second Opinion Market Share, By Disorder, 2022 & 2031 (%)

Figure 35 Middle East & Africa Medical Second Opinion Market Share, By Service Provider, 2022 & 2031 (%)

Figure 36 Mediguide International LLC: Financials

Figure 37 WorldCare Inc.: Financials

Figure 38 Cynergy Care: Financials

Figure 39 AXA PPP Healthcare: Financials

Figure 40 Cleveland Clinic: Financials

Figure 41 Helsana Group: Financials

Figure 42 Teladoc Health: Financials

Figure 43 GrandOpinion: Financials

Figure 44 Lybrate: Financials

Figure 45 Mass General Brigham: Financials